Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1276-1283

  Chen, Living ^a   Nichols, Wilmer W ^a   Mattsson, Christer ^c   Teger Nilsson, Ann Catrine ^c   Saldeen, Tom G P ^b   Mehta, Jawahar L ^a,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTITHROMBIN; INOGATRAN; THROMBIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY REPERFUSION; DOG; DRUG EFFECT; DRUG SCREENING; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME;

ANIMALS; DOGS; FEMALE; GLYCINE; HEMODYNAMIC PROCESSES; MALE; MOLECULAR WEIGHT; PIPERIDINES; THROMBIN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030426813     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ANTWAN, E. M.: Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 90: 1624-1630, 1994.
2. ARMSTRONG, P. W., BAIGRIE, R. S. AND DALY, P. A.: Tissue plasminogen activator Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J. Am. Coll. Cardiol. 13: 1469-1476, 1989.
3. BADIMON, L., LASSILA, R., BADIMON, J. J., VALLABHAJOSULA, S., CHESEBRO, J. H. AND FUSTER, V.: Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 78: 119, 1988.
4. EIDT, J. F., ALLISON, P., NOBLE, S. ASHTON, J., GOLINO, P. MCNATT, J., BUJA, L. M. AND WILLERSON, J. T.: Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 84: 18-27, 1989.
5. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 86: 7585-7589, 1989.
6. FOLTS, J. D., GALLAGHER, K. AND ROWE, G. G.: Blood flow reduction in stenosed canine coronary arteries: Vasospasm or platelet aggregation? Circulation 65: 248-254, 1982.
7. GAST, A., TSCHOPP, T. B., SCHMID, G. AND ACKERMAN, J.: Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240) and, recombinant hirudin. Fibrinolysis 6: 879-887, 1994.
8. GOLD, H. K., LEINBACH, R. C., GARABEDIAN, H. D., YASUDA, T., JOHNS, J. A., GROSSBARD, E. B., PALACIOS, I. AND COLLEN, D.: Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: Prevention by a maintenance infusion. Circulation 73: 347-352, 1986.
9. GULBA, D. C., BARTHELS, M., REIL, G. H. AND LICHTLEN, P. R.: Thrombin/ antithrombin III complex level as early predictor of reocclusion after successful thrombolysis. Lancet 2: 97-99, 1988.
10. HARKER, L. A. AND MANN, K. G.: Thrombolysis and fibrinolysis. In: Thrombosis in Cardiovascular Disorders, ed. by V. Fuster and M. Verstraete, Philadelphia, W. B. Saudners, pp. 1-16, 1992.
11. HASKEL, E. J., PRAGER, N. A., SOBEL, B. E. AND ABENDSCHEIN, D. R.: Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83: 1048-1056, 1991.
12. HERAS, M., CHESEBRO, J. H., WEBSTER, M. W. I., MRUK, J. S., GRILL, D. E., PENNY, W. J., BOWIE, E. W. J., BADIMON, L. AND FUSTER, V.: Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 82: 1476-1484, 1990.
13. HOGG, P. J. AND JACKSON, C. M.: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc. Natl. Acad. Sci. USA 86: 3619-23, 1989.
14. JANG, I. K., GOLD, H. K., ZISKIND, A. A., FALLON, J. T., HOLT, R. E., LEINBACH, R. C., MAY, J. W., AND COLLEN, D.: Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary thrombolysis. Circulation 79: 920-928, 1989.
15. LEE, C. D. AND MANN, K. G.: Activation/inactivation of human factor V by plasmin. Blood 73: 185-190, 1989.
16. LUCORE, C. L. AND SOBEL, B. E.: Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 77: 660-668, 1988.
17. LYNCH, J. J., SITKO, G. R., MELLOTT, M. J., NUTT, E. M., LEHMAN, E. D., FRIEDMAN, P. A., DUNWIDDIE, C. T. AND VLASUK, G. P.: Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy: A comparison of factor Xa versus thrombin inhibition. Cardiovasc. Res. 28: 78-85, 1994.
18. MANN, K. G., NESHEIM, M. E., CHURCH, W. R., HALEY, P. AND KRISHNASWAMY, S.: Surface-dependent reaction of the vitamin K-dependent enzyme complexes. Blood 76: 1-16, 1990a.
19. MATSUO, O., RIJKEN, D. C. AND COLLEN, D.: Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb. Haemoet. 5: 225-229, 1981.
20. MAY, R. D., HAWKESWOOD, E. AND POWLING, M. J.: Superior efficacy of low molecular weight thrombin inhibitors in a novel in vitro model of clot bound thrombin. Blood 84: Suppl 1: 71a, 1994.
21. MEHTA, J. L., NICOLINI, F. A., NICHOLS, W. W. AND SALDEEN T. G. P.: Concurrent nitroglycerine administration decreases thrombolytic potential of tissuetype plasminogen activator. J. Am. Coll. Cardiol. 17: 805-811, 1991.
22. MELLOTT, M. J., CONNOLLY, T. M., YORK, S. J. AND BUSH, L. R.: Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb. Haemost. 64: 526-534, 1990.
23. MILETICH, J. P., JACKSON, C. M. AND MAJERUS, P. W.: Interaciton of coagulation factor Xa with human platelets. Proc. Natl. Acad. Sci. USA 74: 4033-4036, 1977.
24. NEUHAUS, K. L., ESSEN, R. V., TABBE, U., JESSEL, A., HEINRICHS, H., MAURER, W., DORING, W., HARMJANZ, D., KOTTER, V., KALHAMMER, E., SIMON, H. AND HORACEK, T.: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 90: 1638-1642, 1994.
25. NICOLINI, F. A., LEE, P., ROIS, G., KOTTKE-MARCHANT, K. AND TOPOL, E. J.: Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 199489: 1802-1809, 1994.
26. NICOLINI, F. A., MEHTA, J. L., NICHOLS, W. W., SALDEEN, T. G. P. AND GRANT, M.: Prostacyclin analogue iloprost decreases thrombolytic potential of tissuetype plasminogen activator in canine coronary thrombosis. Circulation 181: 1115-1122, 1990.
27. NICOLINI, F. A., NICHOLS, W. W., MEHTA, J. L., SALDEEN, T. G. P., SCHOFIELD, R., Ross, M., PLAYER, D. W., POHL, G. AND MATTSSON, C.: Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue plasminogen activator. J. Am. Coll. Cardiol. 20: 228-235, 1992.
28. NICOLINI, F. A., NICHOLS, W. W., SALDEEN, T. G. P., KHAN, S. AND MEHTA, J. L.: Adjunctive therapy with low molecular weight heparin with rt-PA causes sustained reflow in canine coronary thrombosis. Am. Heart. J. 124: 280-288, 1992b.
29. PRAGER, N. A., TORH-BROWN, S. R., SOBEL, B. E. AND ABENDSCHEIN, D. R.: Mainenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J. Am. Coll. Cardiol. 22: 296-301, 1993.
30. RAPOLD, H. J., KUEMMERLI, H., WEISS, M., BAUR, H. AND HAEBERLI, A.: Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 19: 980-9879, 1989.
31. RIJKEN, D. C., HAYLAVERTS, M. AND COLLEN, D.: Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J. Biol. Chem. 257: 2920-2925, 1982.
32. ROMSON, J. L., HAACK, D. W. AND LUCCHESI, B. R.: Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of anti-thrombotic agents. Thromb. Res. 17: 841-853, 1980.
33. ROSING, J., VAN RIJN, J. L. M., BEVERS, E. M., VAN DIEJEN, G., COMFURIUS, P. AND ZWAAL, R. F. A.: The role of activated human platelets in prothrombin and factor X activation. Blood 5: 319-332, 1985.
34. ROTE, W. E., DUN-XUE, MU., BATES, E. R., NEDELMAN, M. A. AND LUCCHESI, B. R.: Prevention of rethrombosis after coronary thrombolysis in a chronic canine model: II. Adjunctive therapy with hirudin. J. Cardiovasc. Pharmacol. 21: 587-594, 1993.
35. SHENG-KUN, Y., MC NATT, J., ANDERSON, H. V., EIDT, J., CUI, K., GOLINO, P., GLASS-GREENWALT, P., MARAGANORE, J., BULA, L. M. AND WILLERSON, J. T.: Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and reocclusion. Am. J. Physiol. 262: H374-H379, 1992.
36. SITKO, G. R., RAMJIT, D. R., STABILITO, II., LEHMAN, D., LYNCH, J. J. AND VLASUK, G. P.: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tic anticoagulant peptide: Comparison to hirudin and heparin in a canine model of acute coronary artery thrombolysis. Circulation 85: 805-815, 1992.
37. TEGER-NILSSON, A.-C., GYZANDER, E., ANDERSSON, S., ENGLUND, M., MATTSSON, C., ULVINGE, J.-C. AND GUSTAVSSON, D.: In vitro properties of inogatran, a new low molecular weight inhibitor of thrombin. Thromb. Haemost. 73: 1325, 1995.
38. THE TIMI STUDY GROUP: The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N. Engl. J. Med. 312: 932-936, 1985.
39. TOPOL, E. J., FUSTER, V., HARRINOTON, R. A., CALIFF, R. M., KLEIMAN, N. S., KEREIAKS, D. J., COHEN, M., CHAPEKIS, A., GOLD, H. K., TANNENBAUM, M. A., RAO, A. K., DEBOWEY, D., SCHWARTZ, D., HENIS, M. AND CHESEBRO, J.: Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial. Circulation 89: 1557-1566, 1994.
40. YASUDA, T., GOLD, H. K., YAOITA, H., LEINBACH, R. C., GUERRERO, J. I., JANG, I.-K., HOLT, R., FALLON, J. T., AND COLLEN, D.: Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine model. J. Am. Coll. Cardiol. 16: 714-722, 1990.